Prediction Rules of Ludwig for Response to Erythropoietin in a Patient with Cancer and Chronic Anemia

Purpose: To determine if a patient with cancer and chronic anemia is likely to respond to erythropoietin (EPO) therapy.

Info MyLikes MyPaths

Evaluation

Are you evaluating a patient with cancer and chronic anemia for responsiveness to erythropoietin administration?

Yes

Have you excluded obvious nutritional deficiencies and sources of chronic blood loss as the cause for the anemia?

Yes

Hemoglobin before starting therapy

Hemoglobin after 2 weeks of therapy

Serum erythropoietin after 2 weeks of therapy

mU/mL

Serum ferritin after 2 weeks of therapy

Results

Please fill out required fields.

Results Interpretation and Description References Next Steps

Data complete?

Evaluation appropriate?

Is an additional workup of the patient warranted before evaluating effectiveness of EPO?

Change in hemoglobin over the 2 weeks

Prediction of response based on EPO level and change in hemoglobin

Prediction of response based on serum ferritin

Is there any benefit in continuing erythropoietin therapy?

MedicalAlgorithms.com APIs

Power Your Solutions with 5,000+ Automated Medical Analytics

Seamlessly integrate our API library of over 5,000 evidence-based medical analytics into your products and workflows. Our APIs help you:

Build custom, automated clinical workflows tailored to your organization's needs.
Enhance your clinical decision support with advanced, evidence-based analytics.
Streamline revenue cycle management by integrating clinical analytics into billing, coding, and compliance processes.
Support payment and pre-approval processes with automated, standardized medical criteria.
Embed proven medical algorithms directly into your systems and services for consistent, high-quality outcomes.

With MedicalAlgorithms.com APIs, you can accelerate innovation, improve efficiency, and deliver more accurate, data-driven care—without reinventing the wheel.

Explore Medal API

Caution: A qualified health practitioner should verify all results.
Keep patient data confidential and comply with all legal requirements.

Please visit our website Medicalalgorithms.com for Description and Interpretation and further algorithms you may want to consider in the next steps of your evaluation. All information should be verified by a qualified health professional, and all use is subject to Medicalalgorithms.com Terms and Conditions. © Copyright Medicalalgorithms.com Limited

Interpretation and Description

References

Next Steps in Evaluation

Therapy

Selection
- Score of Hellstrom-Lindberg for Predicting Response to Erythropoietin Plus Granulocyte Colony Stimulating Factor in an Anemic Patient with Myelodysplasia
Administration
- Score of Hellstrom-Lindberg for Predicting Response to Erythropoietin Plus Granulocyte Colony Stimulating Factor in an Anemic Patient with Myelodysplasia

Monitoring

Response To Therapy
- Score of Hellstrom-Lindberg for Predicting Response to Erythropoietin Plus Granulocyte Colony Stimulating Factor in an Anemic Patient with Myelodysplasia

Specialty

Hematology Oncology
Clinical Laboratory

Objective

administration
response to therapy
adverse effects
drug levels

ICD-10

C00-D49 - Neoplasms
D55-D59 - Haemolytic anaemias
D60-D64 - Aplastic and other anaemias
D63 - Anaemia in chronic diseases classified elsewhere

Info

Purpose: To determine if a patient with cancer and chronic anemia is likely to respond to erythropoietin (EPO) therapy.

Specialty: Hematology Oncology, Clinical Laboratory

Objective: administration, response to therapy, adverse effects, drug levels

ICD-10: C00-D49, D55-D59, D60-D64, D63,

Save Data

Identifier

Enter 1 to 5 characters as ID

Email

Your registered email

Other

Email to

Please separate multiple email IDs with comma (,)

Consult Report

Identifier

Enter 1 to 5 characters as ID

Add to MyPath

Select path

New path